SS
VRDN icon

SBI Securities’s Viridian Therapeutics VRDN Stock Holding History

SBI Securities’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.4K Buy
567
+209
+58% +$3.37K ﹤0.01% 1814
2026
Q1 		$7K Buy
358
+247
+223% +$7.34K ﹤0.01% 1887
2025
Q4 		$3.45K Buy
111
+70
+171% +$1.92K ﹤0.01% 2177
2025
Q3 		$885 Sell
41
-9
-18% -$162 ﹤0.01% 2748
2025
Q2 		$699 Hold
50
– – ﹤0.01% 2829
2025
Q1 		$674 Sell
50
-4
-7% -$68 ﹤0.01% 2748
2024
Q4 		$1.03K Buy
+54
New +$1.17K ﹤0.01% 2594

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

SBI Securities's VRDN Position: Q2 2026 in Review

SBI Securities increased its Viridian Therapeutics (VRDN) stake by 58% in Q2 2026, buying an estimated $3.37K and bringing the position to 567 shares worth $10.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1814.

SBI Securities first reported a position in VRDN in Q4 2024 and has held it in 7 quarters since. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • SBI Securities held 567 shares of Viridian Therapeutics worth $10.4K as of Q2 2026.
  • SBI Securities bought 209 Viridian Therapeutics shares in Q2 2026, an estimated $3.37K.
  • Viridian Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #1814 holding.
  • SBI Securities first reported a position in Viridian Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.